An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Parkinson, Lynne ^a   Doljagore, Xenia ^a   Gibson, Richard ^a   Doran, Evan ^a   Notley, Lisa ^a   Stewart Williams, Jenny ^a   Kowal, Paul ^a   Byles, Julie E ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; LACTONE; ROFECOXIB; SULFONE;

AGED; ARTICLE; AUSTRALIA; DRUG CONTRAINDICATION; DRUG RECALL; FEMALE; HUMAN; LONGITUDINAL STUDY;

AGED; AGED, 80 AND OVER; AUSTRALIA; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LACTONES; LONGITUDINAL STUDIES; SAFETY-BASED DRUG WITHDRAWALS; SULFONES;

EID: 82055181659     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-892     Document Type: Article

References (55)

1. Emerging from the shadow of Vioxx. Lindsley CW, Curr Top Med Chem 2007 7 7 739 10.2174/156802607780487777 17450647 (Pubitemid 46681855)
2. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Barozzi N, Tett SE, Pharmacoepidemiol Drug Saf 2007 16 11 1184 1191 10.1002/pds.1451 17636557 (Pubitemid 350120642)
3. New drugs: weighing up the risks and benefits. National Prescribing Service, NPS News 2005 43 1
4. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Kerr SJ, Mant A, Horn FE, McGeechan K, Sayer GP, Med J Aust 2003 179 8 403 407 14558862 (Pubitemid 37328004)
5. NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. Roughead EE, Ramsay E, Pratt N, Gilbert AL, Drug Saf 2008 31 11 997 1003 10.2165/00002018- 200831110-00004 18840019
6. Celebrex capsules (celecoxib) NDA 20-998/S-009 medical officer review. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1-19-T-FDA-Tab-L-1.htm
7. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al. N Engl J Med 2000 343 21 1520 1528 10.1056/ NEJM200011233432103 11087881
8. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, et al. N Engl J Med 2005 352 11 1092 1102 10.1056/NEJMoa050493 15713943 (Pubitemid 40365350)
9. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, N Engl J Med 2005 352 11 1071 1080 10.1056/NEJMoa050405 15713944 (Pubitemid 40365348)
10. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR, Lancet 2002 360 9339 1071 1073 10.1016/S0140-6736(02)11131-7 12383990
11. COX-2 inhibitors - a lesson in unexpected problems. Drazen JM, N Engl J Med 2005 352 11 1131 1132 10.1056/NEJMe058038 15713947 (Pubitemid 40365355)
12. Factors associated with celecoxib and rofecoxib utilization. Rawson NSB, Nourjah P, Grosser SC, Graham DJ, Ann Pharmacother 2005 39 4 597 602 10.1345/aph.1E298 15755796 (Pubitemid 40396610)
13. Drug insight: cyclo-oxygenase-2 inhibitors - a critical appraisal. Hinz B, Renner B, Brune K, Nat Clin Pract Rheumatol 2007 3 10 552 560 quiz 551 p following 589 10.1038/ncprheum0619 17906610 (Pubitemid 47506013)
14. Expanded information on cox-2 inhibitors for doctors and pharmacists. http://www.tga.gov.au/archive/media-2005-cox2-050210.htm
15. Expenditure and prescriptions twelve months to 30 June 2006. http://www.health.gov.au/internet/main/publishing.nsf/Content/ 3E527DC621A127C7CA25745100005529/$File/complete.pdf
16. Lumiracoxib (PREXIGE): urgent medicine recall. http://www.tga.gov.au/ safety/recalls-medicine-lumiracoxib-070810.htm
17. Minimising the risk of using analgesics for musculoskeletal pain. National Prescribing Service, NPS News 2003 28 3
18. COX-2 selective inhibitors in the treatment of osteoarthritis. Laine L, White WB, Rostom A, Hochberg M, Semin Arthritis Rheum 2008 38 3 165 187 10.1016/j.semarthrit.2007.10.004 18177922
19. 4 years after withdrawal of rofecoxib: where do we stand today? Jaksch W, Dejaco C, Schirmer M, Rheumatol Int 2008 28 12 1187 1195 10.1007/s00296-008- 0650-4 18663451
20. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. McGettigan P, Henry D, JAMA 2006 296 13 1633 1644 10.1001/jama.296.13.jrv60011 16968831 (Pubitemid 44511610)
21. The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. Williams D, Singh M, Hind C, Br J Clin Pharmacol 2006 62 3 366 368 10.1111/j.1365-2125.2006.02691.x 16934053 (Pubitemid 44215537)
22. Characterizing new users of NSAIDs before and after rofecoxib withdrawal. Usher C, Bennett K, Teeling M, Feely J, Br J Clin Pharmacol 2007 63 4 494 497 10.1111/j.1365-2125.2006.02784.x 17054665 (Pubitemid 46426633)
23. What therapies have replaced rofecoxib in Ireland? Teeling M, O'Connor H, Feely J, Bennett K, Br J Clin Pharmacol 2007 64 4 536 541 10.1111/j.1365-2125. 2007.02918.x 17555468 (Pubitemid 47404306)
24. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Sun SX, Lee KY, Bertram CT, Goldstein JL, Curr Med Res Opin 2007 23 8 1859 1866 10.1185/030079907X210561 17605893 (Pubitemid 47300385)
25. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Sukel MP, van der Linden MW, Chen C, Erkens JA, Herings RM, Pharmacoepidemiol Drug Saf 2008 17 1 9 19 10.1002/pds.1508 17963198 (Pubitemid 351166613)
26. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Alacqua M, Trifiro G, Cavagna L, Caporali R, Montecucco CM, Moretti S, Tari DU, Galdo M, Caputi AP, Arcoraci V, Arthritis Rheum 2008 59 4 568 574 10.1002/art.23526 18383398 (Pubitemid 351563541)
27. Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Setakis E, Leufkens HG, van Staa TP, Arthritis Rheum 2008 59 8 1105 1111 10.1002/art.23925 18668614
28. Analgesic prescribing for musculoskeletal complaints in the ambulatory care setting after the introduction and withdrawal of cyclooxygenase-2 inhibitors. Wilson RD, Arch Phys Med Rehabil 2009 90 7 1147 1151 10.1016/j.apmr.2009.01.017 19577028
29. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals. Schussel K, Schulz M, Pharmazie 2006 61 10 878 886 17069430 (Pubitemid 44622305)
30. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs. Bennett K, Teeling M, Feely J, Eur J Clin Pharmacol 2003 59 8-9 645 649 10.1007/s00228-003-0661-8 12942226 (Pubitemid 37494533)
31. Women's Health Australia: recruitment for a national longitudinal cohort study. Brown WJ, Bryson L, Byles JE, Dobson AJ, Lee C, Mishra G, Schofield M, Women Health 1998 28 1 23 40 10022055 (Pubitemid 29097222)
32. Cohort Profile: the Australian Longitudinal Study on Women's Health. Lee C, Dobson AJ, Brown WJ, Bryson L, Byles J, Warner-Smith P, Young AF, Int J Epidemiol 2005 34 5 987 991 10.1093/ije/dyi098 15894591 (Pubitemid 41535539)
33. Department of Primary Industries and Energy, Rural, remote and metropolitan areas classification: 1991 census edition Canberra: Australian Government Publishing Service 1994
34. BMI classification. http://apps.who.int/bmi/index.jsp?introPage=intro-3. html
35. Use and costs of medications and other health care resources: findings from the Australian Longitudinal Study on Women's Health. Byles J, Loxton D, Berecki J, Dolja-Gore X, Gibson R, Hockey R, Robinson I, Parkinson L, Adamson L, Lucke J, et al. 2008
36. Health services research using linked records: who consents and what is the gain? Young AF, Dobson AJ, Byles JE, Aust N Z J Public Health 2001 25 5 417 420 11688619 (Pubitemid 32952042)
37. Australian statistics on medicines 2003. http://www.health.gov.au/ internet/main/publishing.nsf/content/health-pbs-general-pubs-asm.htm
38. How do different age groups use benzodiazepines and antidepressants? Analysis of an Australian administrative database, 2003-6. Smith AJ, Tett SE, Drugs Aging 2009 26 2 113 122 10.2165/0002512-200926020-00003 19220068
39. Australian Tax Office Foreign exchange rates prior to 01 July 2003. http://www.ato.gov.au/taxprofessionals/content.aspx?doc=/content/1261.htm
40. The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD). http://www.who.int/classifications/atcddd/en/
41. Australian medicines handbook Adelaide: Australian Medcines Handbook Pty Ltd 2009
42. Replacing hormone therapy - is the decline in prescribing sustained, and are nonhormonal drugs substituted? Vegter S, Kolling P, Toben M, Visser ST, de Jong-van den Berg LT, Menopause 2009 16 2 329 335 10.1097/gme.0b013e31818c046b 19188855
43. Measuring disease occurrence and causal effects. Rothman KJ, Epidemiology: An introduction New York: Oxford University Press 2002 24 56
44. SAS Institute Inc, SAS/STAT 9.2 User's Guide Cary, NC: SAS Institute Inc 2008
45. Arthritis burden and impact are greater among U.S. women than men: intervention opportunities. Theis KA, Helmick CG, Hootman JM, J Womens Health (Larchmt) 2007 16 4 441 453 10.1089/jwh.2007.371 (Pubitemid 46954787)
46. Arthritis in Canada: An ongoing challenge. http://www.phac-aspc.gc.ca/ publicat/ac/pdf/ac-e.pdf
47. Office for National Statistics 2006. Focus on Health, 2005. http://www.ons.gov.uk/ons/rel/disability-and-health-measurement/focus-on-health/ 2005-edition/focus-on-health - -full-report.pdf
48. The voice of arthritis: A social impact study of arthritis in Australia. http://www.arthritisaustralia.com.au/index.php/reports/the-voice-of-arthritis- 2004.html
49. Arthritis-the bottom line: The economic impact of arthritis in Australia. http://www.arthritisaustralia.com.au/index.php/reports/arthritis-the-bottom- line-2005.html
50. Accuracy of telephone self-report of drug use in older people and agreement with pharmaceutical claims data. Pit SW, Byles JE, Cockburn J, Drugs Aging 2008 25 1 71 80 10.2165/00002512-200825010-00008 18184031
51. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey. Steinfeld S, Poriau S, Curr Med Res Opin 2001 17 2 81 87 11759186 (Pubitemid 32963997)
52. Vioxx withdrawal - an opportunity to review primary care management for osteoarthritis. Lee A, Hong Kong Med J 2005 11 2 135 15815072 (Pubitemid 40545520)
53. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Courtney PDM, Ann Rheum Dis 2002 61 767 773 10.1136/ard.61.9.767 12176799
54. Therapeutic guidelines: Analgesic. Melbourne: Therapeutic Guidelines: Analgesic Writing Group 4 2002
55. Cyclooxygenase-2 inhibitors: what went wrong? James MJ, Cleland LG, Curr Opin Clin Nutr Metab Care 2006 9 2 89 94 10.1097/01.mco.0000214565.67439.83 16477171 (Pubitemid 44090030)